Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2008

Open Access 01-12-2008 | Research article

Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses

Authors: L Reilly, C Magkrioti, T Mduluza, DR Cavanagh, F Mutapi

Published in: BMC Infectious Diseases | Issue 1/2008

Login to get access

Abstract

Background

The overlapping geographical and socio-economic distribution of malaria and helminth infection has led to several studies investigating the immunological and pathological interactions of these parasites. This study focuses on the effect of treating schistosome infections on natural human immune responses directed against plasmodia merozoite surface proteins MSP-1 (DPKMWR, MSP119), and MSP-2 (CH150 and Dd2) which are potential vaccine candidates as well as crude malaria (schizont) and schistosome (whole worm homogenate) proteins.

Methods

IgG1 and IgG3 antibody responses directed against Schistosoma haematobium crude adult worm antigen (WWH) and Plasmodium falciparum antigens (merozoite surface proteins 1/2 and schizont extract), were measured by enzyme linked immunosorbent assay (ELISA) in 117 Zimbabweans (6–18 years old) exposed to S. haematobium and P. falciparum infection. These responses were measured before and after anti-helminth treatment with praziquantel to determine the effects of treatment on anti-plasmodial/schistosome responses.

Results

There were no significant associations between antibody responses (IgG1/IgG3) directed against P. falciparum and schistosomes before treatment. Six weeks after schistosome treatment there were significant changes in levels of IgG1 directed against schistosome crude antigens, plasmodia crude antigens, MSP-119, MSP-2 (Dd2), and in IgG3 directed against MSP-119. However, only changes in anti-schistosome IgG1 were attributable to the anti-helminth treatment.

Conclusion

There was no association between anti-P. falciparum and S. haematobium antibody responses in this population and anti-helminth treatment affected only anti-schistosome responses and not responses against plasmodia crude antigens or MSP-1 and -2 vaccine candidates.
Appendix
Available only for authorised users
Literature
1.
Sachs J, Malaney P: The economic and social burden of malaria. Nature. 2002, 415 (6872): 680-685. 10.1038/415680a.CrossRefPubMed
2.
Chitsulo L, Engels D, Montresor A, Savioli L: The global status of schistosomiasis and its control. Acta Trop. 2000, 77 (1): 41-51. 10.1016/S0001-706X(00)00122-4.CrossRefPubMed
3.
Diallo TO, Remoue F, Schacht AM, Charrier N, Dompnier JP, Pillet S, Garraud O, N'Diaye AA, Capron A, Capron M, et al: Schistosomiasis co-infection in humans influences inflammatory markers in uncomplicated Plasmodium falciparum malaria. Parasite Immunol. 2004, 26 (8–9): 365-369. 10.1111/j.0141-9838.2004.00719.x.CrossRefPubMed
4.
Lyke KE, Dabo A, Sangare L, Arama C, Daou M, Diarra I, Plowe CV, Doumbo OK, Sztein MB: Effects of concomitant Schistosoma haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in Malian children. Infect Immun. 2006, 74 (10): 5718-5724. 10.1128/IAI.01822-05.CrossRefPubMedPubMedCentral
5.
Hartgers FC, Yazdanbakhsh M: Co-infection of helminths and malaria: modulation of the immune responses to malaria. Parasite Immunol. 2006, 28 (10): 497-506. 10.1111/j.1365-3024.2006.00901.x.CrossRefPubMed
6.
Druilhe P, Sauzet JP, Sylla K, Roussilhon C: Worms can alter T cell responses and induce regulatory T cells to experimental malaria vaccines. Vaccine. 2006, 24 (23): 4902-4904. 10.1016/j.vaccine.2006.03.018.CrossRefPubMed
7.
Helmby H: Schistosomiasis and malaria: another piece of the crossreactivity puzzle. Trends Parasitol. 2007, 23 (3): 88-90. 10.1016/j.pt.2007.01.001.CrossRefPubMed
8.
Naus CW, Jones FM, Satti MZ, Joseph S, Riley EM, Kimani G, Mwatha JK, Kariuki CH, Ouma JH, Kabatereine NB, et al: Serological responses among individuals in areas where both schistosomiasis and malaria are endemic: cross-reactivity between Schistosoma mansoni and Plasmodium falciparum. J Infect Dis. 2003, 187 (8): 1272-1282. 10.1086/368361.CrossRefPubMed
9.
Mutapi F, Ndhlovu PD, Hagan P, Spicer JT, Mduluza T, Turner CM, Chandiwana SK, Woolhouse MEJ: Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis. 1998, 178: 289-293.CrossRefPubMed
10.
Scott J, Turner C, Mutapi F, Woolhouse MEJ, Chandiwana SK, Mduluza T, Ndhlovu PD, Hagan : Dissociation of interleukin-4 and interleukin-5 production following treatment for Schistosoma haematobium infection in humans. Parasite Immunol. 2000, 22 (2): 341-348. 10.1046/j.1365-3024.2000.00311.x.CrossRefPubMed
11.
Mutapi F, Burchmore R, Foucher A, Harcus Y, Nicoll G, Midzi N, Turner C, Maizels R: Praziquantel treatment of people exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J Infect Dis. 2005, 192 (6): 1108-1118. 10.1086/432553.CrossRefPubMed
12.
Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, Akanmori BD, Polley S, Conway DJ, Koram K, McBride JS: Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun. 2004, 72 (11): 6492-6502. 10.1128/IAI.72.11.6492-6502.2004.CrossRefPubMedPubMedCentral
13.
Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, et al: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1–2b trial in Papua New Guinea. J Infect Dis. 2002, 185 (6): 820-827. 10.1086/339342.CrossRefPubMed
14.
Bouharoun-Tayoun H, Druihle P: Plasmodium falciparum: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun. 1992, 60: 1473-1481.PubMedPubMedCentral
15.
Mutapi F, Hagan P, Ndhlovu P, Woolhouse MEJ: Comparison of humoral responses to Schistosoma haematobium in areas with high and low levels of infection. Parasite Immunol. 1997, 19: 255-263. 10.1046/j.1365-3024.1997.d01-206.x.CrossRefPubMed
16.
Cavanagh DR, McBride JS: Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. Mol Biochem Parasitol. 1997, 85 (2): 197-211. 10.1016/S0166-6851(96)02826-5.CrossRefPubMed
17.
Cavanagh DR, Elhassan IM, Roper C, Robinson VJ, Giha H, Holder AA, Hviid L, Theander TG, Arnot DE, McBride JS: A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol. 1998, 161 (1): 347-359.PubMed
18.
Ndhlovu P, Cadman H, Vennervald BJ, Christensen NO, Chidimu N, Chandiwana SK: Age-related antibody profiles in Schistosoma haematobium in a rural community in Zimbabwe. Parasite Immunol. 1996, 18: 181-191. 10.1046/j.1365-3024.1996.d01-78.x.CrossRefPubMed
19.
Correa-Oliveira R, Caldas RI, Gazzinelli G: Natural versus drug-induced resistance in Schistosoma mansoni infection. Parasitol Today. 2000
20.
Taylor P, Mutambu SL: A review of the malaria situation in Zimbabwe with special reference to the period 1972–1981. Trans R Soc Trop Med Hyg. 1986, 80: 12-19. 10.1016/0035-9203(86)90185-9.CrossRefPubMed
21.
22.
Mabaso ML, Craig M, Vounatsou P, Smith T: Towards empirical description of malaria seasonality in southern Africa: the example of Zimbabwe. Trop Med Int Health. 2005, 10 (9): 909-918. 10.1111/j.1365-3156.2005.01462.x.CrossRefPubMed
23.
Mabaso ML, Vounatsou P, Midzi S, Da Silva J, Smith T: Spatio-temporal analysis of the role of climate in inter-annual variation of malaria incidence in Zimbabwe. Int J Health Geogr. 2006, 5: 20-10.1186/1476-072X-5-20.CrossRefPubMedPubMedCentral
24.
Mharakurwa S, Mutambu SL, Mudyiradima R, Chimbadzwa T, Chandiwana SK, Day KP: Association of house spraying with suppressed levels of drug resistance in Zimbabwe. Malar J. 2004, 3: 35-10.1186/1475-2875-3-35.CrossRefPubMedPubMedCentral
25.
Katz N, Chaves A, Pellegrino J: A simple device for quantitative stool thick smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1972, 14: 397-400.PubMed
26.
Mott KE: A reusable polyamide filter for diagnosis of S. haematobium infection by urine filtration. Bull Soc Pathol Exot Filiales. 1983, 76 (1): 101-104.PubMed
27.
Mutapi F, Mduluza T, Gomez-Escobar N, Gregory WF, Fernandez C, Midzi N, Maizels RM: Immuno-epidemiology of human Schistosoma haematobium infection: preferential IgG3 antibody responsiveness to a recombinant antigen dependent on age and parasite burden. BMC Infect Dis. 2006, 6: 96-10.1186/1471-2334-6-96.CrossRefPubMedPubMedCentral
28.
Aribot G, Rogier C, Sarthou JL, Trape JF, Balde AT, Druilhe P, Roussilhon C: Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg. 1996, 54 (5): 449-457.PubMed
29.
Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P: Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood. 1994, 84 (5): 1594-1602.PubMed
30.
Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, Jepsen S, Druilhe P: The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun. 1998, 66 (1): 11-17.PubMedPubMedCentral
31.
Sokal RR, Rohlf J: Biometry: the principles and practice of statistics in biological research. Freeman and Company. 1995
32.
Sharma S: Applied multivariate techniques. 1996, New York: John Wiley and Sons
33.
Mutapi F, Roddam A: p-values for pathogens: statistical inference from infectious-disease data. Lancet Infect Dis. 2002, 2: 219-230. 10.1016/S1473-3099(02)00240-2.CrossRefPubMed
34.
Grafen A, RHails R: Modern statistics for the life sciences. 2002, Oxford Univeristy Press
35.
Wilson S, Jones FM, Mwatha JK, Kimani G, Booth M, Kariuki HC, Vennervald BJ, Ouma JH, Muchiri E, Dunne DW: Hepatosplenomegaly is associated with low regulatory and Th2 responses to schistosome antigens in childhood schistosomiasis and malaria coinfection. Infect Immun. 2008, 76 (5): 2212-2218. 10.1128/IAI.01433-07.CrossRefPubMedPubMedCentral
36.
Mutapi F: Heterogeneities in anti-schistosome humoral responses following chemotherapy. Trends Parasitol. 2001, 17 (11): 518-524. 10.1016/S1471-4922(01)02118-3.CrossRefPubMed
37.
Taylor RR, Allen SJ, Greenwood BM, Riley EM: IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical malaria. Am J Trop Med Hyg. 1998, 58: 406-413.PubMed
38.
Miller LH, Roberts T, Shahabuddin M, McCutchan TF: Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol. 1993, 59 (1): 1-14. 10.1016/0166-6851(93)90002-F.CrossRefPubMed
39.
Cavanagh DR, Dobano C, Elhassan IM, Marsh K, Elhassan A, Hviid L, Khalil EA, Theander TG, Arnot DE, McBride JS: Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun. 2001, 69 (2): 1207-1211. 10.1128/IAI.69.2.1207-1211.2001.CrossRefPubMedPubMedCentral
40.
Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM: Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis. 1996, 173 (3): 765-769.CrossRefPubMed
41.
Mutapi F, Roussilhon C, Mduluza T, Druilhe P: Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium. Mem Inst Oswaldo Cruz. 2007, 102 (3): 405-409. 10.1590/S0074-02762007005000046.CrossRefPubMed
42.
Weisman S, Wang L, Billman-Jacobe H, Nhan DH, Richie TL, Coppel RL: Antibody responses to infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein 2. Infect Immun. 2001, 69 (2): 959-967. 10.1128/IAI.69.2.959-967.2001.CrossRefPubMedPubMedCentral
43.
McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, Thompson JK, Marshall VM, Coppel RL, Kemp DJ, Anders RF: Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1994, 68 (1): 53-67. 10.1016/0166-6851(94)00149-9.CrossRefPubMed
44.
Sokhna C, Le Hesran JY, Mbaye PA, Akiana J, Camara P, Diop M, Ly A, Druilhe P: Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal. Malar J. 2004, 3: 43-10.1186/1475-2875-3-43.CrossRefPubMedPubMedCentral
45.
Harnett W: The antihelminthic action of praziquantel. Parasitol Today. 1988, 4 (5): 144-146. 10.1016/0169-4758(88)90192-5.CrossRefPubMed
46.
Kinyanjui SM, Conway DJ, Lanar DE, Marsh K: IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J. 2007, 6: 82-10.1186/1475-2875-6-82.CrossRefPubMedPubMedCentral
Metadata
Title
Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses
Authors
L Reilly
C Magkrioti
T Mduluza
DR Cavanagh
F Mutapi
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2008
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-8-158

Other articles of this Issue 1/2008

BMC Infectious Diseases 1/2008 Go to the issue

Research article

Persistence of the immune response induced by BCG vaccination

Research article

An A2Aadenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models

Research article

Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells

Research article

Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

Research article

Treatment of isoniazid-resistant pulmonary tuberculosis

Research article

Uptake of HIV testing and outcomes within a Community-based Therapeutic Care (CTC) programme to treat Severe Acute Malnutrition in Malawi: a descriptive study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits